Vijay Shah, Kinney Executive Dean of Research Carol Gatton Professor of Medicine Mayo Clinic, shared on LinkedIn:
“FDA approves immunotherapy regimen studied by Mayo Clinic for stage 3 colon cancer based on results from the ATOMIC clinical trial led by Mayo Clinic.
The Food and Drug Administration has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.
The treatment is for patients whose tumors have deficient DNA mismatch repair.
Oncologist Frank Sinicrope, M.D. led the ATOMIC study.”
